INVESTIGATION OF PHYSICAL FITNESS AND GROSS MOTOR CAPACITY IN CHILDREN WITH NEUROFIBROMATOSIS TYPE 1

Öz

Purpose: To assess physical fitness, gross motor capacity, and their relationship in children with neurofibromatosis type 1 (NF1). Materials and Methods: Children with NF1 (n=40, age 6-17, mean 9.70±3.8 years) and typically developing children (TDC) (n= 28, age 5,5-17,5, mean 11.35±3.0 years) were evaluated by the six-minute walking test, sit-up test, sit-and-reach test, flamingo balance test and body mass index. Gross motor capacity was assessed with the Gross Motor Function Measure D and E subdimensions. Results: Physical fitness and gross motor capacity differed significantly between NF1 and TDC (p<0.05). Physical fitness parameters correlated with gross motor capacity to a fair to moderate degree in children with NF1 (r:0.42-0.71; p<0.05). Conclusions: Physical fitness and gross motor capacity are correlated and both are impaired in children with NF1. Exercise programs aiming to increase these functions can be recommended: therefore, areas of intervention can be defined from tests described in this study.

Anahtar Kelimeler

• Neurofibromatosis type 1
• physical fitness
• physiotherapy

NÖROFİBROMATOZİS TİP 1 TANILI ÇOCUKLARDA KABA MOTOR KAPASİTE VE FİZİKSEL UYGUNLUĞUN İNCELENMESİ

Öz

Amaç: Nörofibramatozis Tip 1 (NF1) tanılı çocuklarda kaba motor kapasite, ve fiziksel uygunluğu ve birbirleri arasındaki ilişkiyi değerlendirmektir. Yöntem: NF1'li çocuklar (n=40, yaş 6-17, ortalama 9,70±3.8 yıl) ve tipik gelişen çocuklar (TGÇ) (n= 28, yaş 5,5-17,5, ortalama 11,35±3,0 yıl) altı dakikalık yürüme testi, mekik testi, otur-uzan testi, flamingo denge testi ile değerlendirildi ve vücut kitle indeksi hesaplandı. Kaba motor fonksiyon, Kaba Motor Fonksiyon Ölçütü D ve E alt boyutları ile değerlendirildi. Sonuçlar: Fiziksel uygunluk ve kaba motor kapasite NF1 ve TDC arasında anlamlı farklılık gösterdi (p<0,05). Fiziksel uygunluk parametreleri, NF1'li çocuklarda kaba motor kapasitesi ile orta derecede korelasyon gösterdi (r:0,42-0,71; p<0,05). Tartışma: NF1 tanılı çocuklarda fiziksel uygunluk ve motor kapasite etkilenmiştir ve birbirleri ile ilişkilidirler. Etkilenen fonksiyonları arttırmaya yönelik egzersiz programları önerilebilir. Sonuç olarak; müdahale alanları çalışmamızda tanımlanmış testler ile belirlenebilir.

Anahtar Kelimeler

• Fiziksel Uygunluk
• Fizyoterapi
• Nörofibramatozis tip 1

Kaynakça

1. 1. Solem EP, Primiano M, McQuillen MP, et al. Factors associated with parental knowledge of neurofibromatosis type 1 (NF1): Parental affected status and genetic counseling. J Genet Couns. 2020;00:1-8.
2. 2. Miller DT, Freedenberg D, Schorry E, et al. Health Supervision for Children With Neurofibromatosis Type 1. Pediatrics. 2019;143(5):e20190660.
3. 3. Summers MA, Quinlan KG, Payne JM, et al. Skeletal muscle and motor deficits in Neurofibromatosis Type 1. J Musculoskelet Neuronal Interact. 2015;15(2):161‐170.
4. 4. Cornett KM, North KN, Rose KJ, Burns J. Muscle weakness in children with neurofibromatosis type 1. Dev Med Child Neurol. 2015;57(8):733‐736.
5. 5. Shumway-Cook, A., & Woollacott, M. H. Motor control: translating research into clinical practice. 5th ed. Maryland; Lippincott Williams & Wilkins; 2007.
6. 6. Østensjø, S., Carlberg, E. B., & Vøllestad, N. K. Motor impairments in young children with cerebral palsy: relationship to gross motor function and everyday activities. Dev Med Child Neurol, 2004;46(9), 580-589.
7. 7. Lee, B. H. Relationship between gross motor function and the function, activity and participation components of the International Classification of Functioning in children with spastic cerebral palsy. JPTS, 2017;29(10), 1732-1736.
8. 8. Reedman, S., Boyd, R. N., & Sakzewski, L. The efficacy of interventions to increase physical activity participation of children with cerebral palsy: A systematic review and meta‐analysis. Dev Med Child Neurol, 2017;59(10), 1011-1018.

9. 9. Roy, T. C., Springer, B. A., McNulty, V. et al. Physical fitness. Military Med, 2010; 175(8): 14-20.
10. 10. Johnson BA, Macwilliams B, Carey JC, et al. Lower extremity strength and hopping and jumping ground reaction forces in children with neurofibromatosis type 1. Hum Mov Sci. 2012;31(1):247‐254.
11. 11. de Souza JF, Araújo CG, de Rezende NA, et al. Exercise capacity impairment in individuals with neurofibromatosis type 1. Am J Med Genet A. 2013;161(2):393‐395.
12. 12. National Institutes of Health Consensus Development Conference Statement: neurofibromatosis. Bethesda, Md., USA, July 13–15, 1987. Neurofibromatosis. 1988;1:172–178.
13. 13. Mei, Z., Grummer-Strawn, L. M., Pietrobelli, A., et. Al. Validity of body mass index compared with other body-composition screening indexes for the assessment of body fatness in children and adolescents. J CLIN NUTR. 2002;75(6):978-985.
14. 14. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166(1):111‐117.
15. 15. Geiger R, Strasak A, Treml B, et al. Six-minute walk test in children and adolescents. J Pediatr. 2007;150(4):395‐399.e3992.
16. 16. Kozlowski KF, Lopata C, Donnelly JP, et al. Feasibility and Associated Physical Performance Outcomes of a High-Intensity Exercise Program for Children With Autism Res Q Exerc Sport. 2020;1‐12.
17. 17. Cornbleet SL, Woolsey NB. Assessment of hamstring muscle length in school-aged children using the sit-and-reach test and the inclinometer measure of hip joint angle. Phys Ther. 1996;76(8):850‐855.
18. 18. Erikoğlu G, Özkamçı H, Golmoghanı N, et al. Assesment of Performance Parameters With Eurofit Test Battery According to Gender and Age Groups at 7-12 Years Old Children. GaziBESBD. 2009;14(4): 49-64.
19. 19. Russell D, Palisano R, Walter S, et al. Evaluating motor function in children with Down syndrome: validity of the GMFM. Dev Med Child Neurol. 1998;40(10):693‐701. 20. Akoglu H. User's guide to correlation coefficients. Turk J Emerg Med. 2018;18(3):91‐93.
20. 21. Yoon TH, Mun YK, Lee JS, et al. Analysis for reliability and validity of gross motor function and health fitness tests for children with developmental disabilities. J Exerc Rehabil. 2019;15(5):667‐675.
21. 22. Zaqout M, Vyncke K, Moreno LA, et al. Determinant factors of physical fitness in European children. Int J Public Health. 2016;61(5):573‐582.
22. 23. Wu SK, Lin HH, Li YC, Tsai CL, Cairney J. Cardiopulmonary fitness and endurance in children with developmental coordination disorder. Res Dev Disabil. 2010;31(2):345‐349.
23. 24. Slaman J, Roebroeck M, van der Slot W, et al. Can a lifestyle intervention improve physical fitness in adolescents and young adults with spastic cerebral palsy? A randomized controlled trial. Arch Phys Med Rehabil. 2014;95(9):1646‐1655.
24. 25. Hockett CW, Eelloo J, Huson SM, et al. Vitamin D status and muscle function in children with neurofibromatosis type 1 (NF1). J Musculoskelet Neuronal Interact. 2013;13(1):111‐119.
25. 26. Souza JF, Passos RL, Guedes AC, et al. Muscular force is reduced in neurofibromatosis type 1. J Musculoskelet Neuronal Interact. 2009;9(1):15‐17.
26. 27. Bar-Or O. Pathophysiological factors which limit the exercise capacity of the sick child. Med Sci Sports Exerc. 1986;18(3):276‐282.
27. 28. Johnson BA, MacWilliams BA, Stevenson DA. Postural control in children with and without neurofibromatosis type 1. Hum Mov Sci. 2014;34:157‐163.
28. 29. Soucy EA, Gao F, Gutmann DH, et al. Developmental delays in children with neurofibromatosis type 1. J Child Neurol. 2012;27(5):641‐644.
29. 30. Lorenzo J, Barton B, Acosta MT, North K. Mental, motor, and language development of toddlers with neurofibromatosis type 1. J Pediatr. 2011;158(4):660‐665.
30. 31. Champion JA, Rose KJ, Payne JM, Burns J, North KN. Relationship between cognitive dysfunction, gait, and motor impairment in children and adolescents with neurofibromatosis type 1. Dev Med Child Neurol. 2014;56(5):468‐474.
31. 32. Singh-Grewal D, Wright V, Bar-Or O, et al. Pilot study of fitness training and exercise testing in polyarticular childhood arthritis. Arthritis Rheum. 2006;55(3):364‐372.